Core Viewpoint - The FDA has approved Zepbound (tirzepatide) as the first drug for treating obstructive sleep apnea in patients with obesity, expanding treatment options beyond traditional methods like CPAP machines [3][4]. Group 1: Drug Approval and Indications - Zepbound is officially indicated for moderate-to-severe obstructive sleep apnea in adults with obesity [4]. - The approval follows a significant study published in the New England Journal of Medicine, demonstrating improvements in both sleep apnea and obesity among patients [4][5]. Group 2: Implications for Patients and Healthcare - The introduction of Zepbound provides new treatment avenues for sleep apnea patients who previously had limited options due to co-morbidities [5]. - There is potential for the FDA to approve additional weight loss drugs for treating sleep apnea in the future, as indicated by medical professionals [4].